Great analysis and good to see some buyers coming since this announcement all be it on low volume.
Perhaps some investors taking into account that as we progress into these trials that there is a greater chance of efficacy as increased dosage is safe and tolerable.
All IMHO.
Ann: First Patient Recruited to Cohort 3 of ACCENT Trial, page-10
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.004(5.41%) |
Mkt cap ! $19.01M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.0¢ | $14.65K | 195.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51009 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 52133 | 1 |
View Market Depth
| Last trade - 15.59pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.004 ( 4.05 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.3¢ | 7.0¢ | 2121 | ||
| Last updated 15.08pm 05/06/2024 ? | |||||
| ATX (ASX) Chart |